TABLE II.

Concurrent chemoradiotherapy with demonstrated survival benefits in solid malignancies

Tumour type	Indication	Chemotherapy agent or agents	Benefit
Head and neck	Locally advanced disease	Cisplatin, 5fu, cetuximab	Improved organ preservation and survival
nsclc	Stage iiib, nonmetastatic inoperable disease	Cisplatin, carboplatin, etoposide, paclitaxel	Curative in poor surgical candidates
sclc	Limited stage disease	Cisplatin, etoposide	Curative in approximately 20%
Esophageal	Locally advanced	Cisplatin, 5fu	Increase cure rate, survival, and organ preservation
Glioblastoma	Adjuvant	Temozolomide	Survival benefit

5fu = 5-fluorouracil; nsclc = non-small-cell lung cancer; sclc = small-cell lung cancer.